Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 175 clinical trials
Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia (FAST)

The hypothesis is that efficient prevention of thrombosis with aspirin at diagnosis becomes less useful once patients have achieved a hematologic response (HR) (modified by amendment 1/03/2017) and/or that this benefit is hampered by an increased hemorrhagic risk especially in elderly patients. Hence, investigator propose a prospective randomized study to …

thrombocytosis
thrombosis
hydroxyurea
aspirin
essential thrombocythemia
  • 3 views
  • 23 Feb, 2022
  • 1 location
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA) (PACIFICA)

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or …

direct bilirubin
international normalized ratio
left upper quadrant pain
thrombocytopenia
neutrophil count
  • 698 views
  • 20 Sep, 2022
  • 75 locations
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

The use of genomics and functional translational studies is to identify and diagnose patients with precursor features of myeloid neoplasms and inherited bone marrow failure syndromes.

  • 6 views
  • 10 Jul, 2022
  • 1 location
Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

The purpose of the study is to evaluate the effectiveness and safety of fedratinib as maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic hematopoietic

  • 0 views
  • 29 Jun, 2022
  • 1 location
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients (AIRPORT-MPN)

Myeloproliferative neoplasms (MPNs) are blood disorders that occur when the body makes too many white or red blood cells, or platelets. This overproduction of blood cells in the bone marrow can

blood thinners
apixaban 2.5 mg
blood clot
eliquis
drug test
  • 0 views
  • 05 May, 2022
  • 1 location
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs

myeloid leukemia
chronic myeloid leukemia
leukemia
  • 0 views
  • 30 Jun, 2022
  • 1 location
Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

myeloproliferative neoplasms (tumors). Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by

cancer
mds/mpd
stem cell transplantation
thrombocytosis
blast crisis
  • 14 views
  • 08 Mar, 2022
  • 1 location
Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm (CPX-351 TA-SMP)

The three classic myeloproliferative neoplasms (MPNs) include polycythemia Vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The natural history of these MPNs is the

blast cells
direct bilirubin
gilbert's syndrome
consolidation therapy
induction chemotherapy
  • 0 views
  • 10 Aug, 2022
  • 20 locations
A Study of Fedratinib With IDH Inhibition in Advanced-Phase IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

The purpose of this research is to gather information on the safety and effectiveness of fedratinib (a drug called a "jak inhibitor" ) in combination with ivosidenib or enasidenib (two anti-cancer drugs). While all three drugs are FDA-approved for various conditions, the US Food and Drug Administration (FDA) has not …

cancer
myelofibrosis
blast cells
leukemia
hydroxyurea
  • 0 views
  • 29 Nov, 2021
  • 1 location
Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients With Myelofibrosis and Myelodysplastic Syndrome/ Myeloproliferative Neoplasm

This phase II trial studies how well ruxolitinib phosphate and azacytidine work in treating patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm. Ruxolitinib

cancer
direct bilirubin
myelodysplastic/myeloproliferative neoplasms
neutrophil count
mds/mpd
  • 226 views
  • 16 Sep, 2022
  • 1 location